4SC AGのEV / EBITDA
4SC AGのEV / EBITDAは何ですか。
4SC AGのEV / EBITDAは0.60です。
EV / EBITDAの定義は何ですか。
EV / EBITDA は、企業価値をEBITDA(利息、税金、減価償却費および償却費を控除する前の利益)で割ったものですです。これは、株価がどれほど高価で、P / E比よりも頻繁に企業をお互いを比較するために使用されます。これは、投資家が会社のキャッシュフローの利益のために支払う価格を測定します。
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
XETRAのセクタHealth CareにおけるEV / EBITDAの企業と比べる4SC AG
4SC AGは何をしますか。
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
4SC AGと類似のev / ebitda
- Satsuma PharmaceuticalsのEV / EBITDAは0.59です。
- QPL InternationalのEV / EBITDAは0.59です。
- Cobra VentureのEV / EBITDAは0.59です。
- Unico AmericanのEV / EBITDAは0.59です。
- QuesterreのEV / EBITDAは0.60です。
- AHAlifeのEV / EBITDAは0.60です。
- 4SC AGのEV / EBITDAは0.60です。
- Guangnan ()のEV / EBITDAは0.61です。
- Enveric BiosciencesのEV / EBITDAは0.61です。
- FibroGen IncのEV / EBITDAは0.61です。
- Silverback TherapeuticsのEV / EBITDAは0.61です。
- Billing ServicesのEV / EBITDAは0.61です。
- STM PlcのEV / EBITDAは0.61です。